RU97113146A - SUBSTITUTED INDANYLIDINACETHYLGUANIDINES, METHOD FOR PRODUCING THEM, USE AS MEDICINES OR DIAGNOSTIC MEDICINES AND MEDICINES CONTAINING THESE COMPOUNDS - Google Patents

SUBSTITUTED INDANYLIDINACETHYLGUANIDINES, METHOD FOR PRODUCING THEM, USE AS MEDICINES OR DIAGNOSTIC MEDICINES AND MEDICINES CONTAINING THESE COMPOUNDS

Info

Publication number
RU97113146A
RU97113146A RU97113146/04A RU97113146A RU97113146A RU 97113146 A RU97113146 A RU 97113146A RU 97113146/04 A RU97113146/04 A RU 97113146/04A RU 97113146 A RU97113146 A RU 97113146A RU 97113146 A RU97113146 A RU 97113146A
Authority
RU
Russia
Prior art keywords
alkyl
formula
alkylaryl
compounds
aryl
Prior art date
Application number
RU97113146/04A
Other languages
Russian (ru)
Other versions
RU2176638C2 (en
Inventor
Венката Сатья Рамакришна Нироги
Кумар Яин Арун
Лал Банси
Венката Сатья Веерабхадра Вадламуди Рао
Вазантрао Гхате Анил
Даттатрайа Гупте Равиндра
Вайхерт Андреас
Шварк Ян-Роберт
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP96112275A external-priority patent/EP0837055A1/en
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU97113146A publication Critical patent/RU97113146A/en
Application granted granted Critical
Publication of RU2176638C2 publication Critical patent/RU2176638C2/en

Links

Claims (17)

1. Инданилидинацетилгуанидин формулы I
Figure 00000001

где R1, R2, R3, R4, R5, R6 в отдельности или совместно представляют собой H, C1-C10 алкил, галогеноалкил, имеющий 1-6 атомов углерода, О-C1-C10-алкил, галогеноалкокси-группу имеющую 1-6 атомов углерода, F, Cl, Br, I, арил, замещенный арил, гетероарил, OH, O-низший алкил, О-арил, О-низший алкиларил, О-замещенный арил, О-низший алкилзамещенный арил, O-C(=O)-C1-C4-алкиларил, O-C(= O)-NH-C1-C4-алкил, O-C(= O)-N-(C1-C4-алкил)2, NO2, CH, CF3, NH2, NH-C(=O)-C1-C4-алкил, NH-C(=O)-NH2, COOH, C(=O)-O-C1-C4-алкил, C(= O)-NH2, C(= O)-NH-C1-C4-алкил, C(= O)-N(C1-C4-алкил)2, C1-C4-COOH, C1-C4-алкил-C(= O)-O-C1-C4-алкил, SO3H, SO2-алкил, SO2-алкиларил, SO2-N-(алкил), SO2-N-(алкил)(алкиларил), C(= O)-R11, C1-C10-алкил-C(= O)-R11, C2-C10-алкенил-C(= O)-R11, C2-C10-алкинил-C(=O)-R11, NH-C(=O)-C1-C10-алкил-C(= O)-R11 или O-C1-C11-алкил-C(=O)-R11, R11 представляет собой C1-C4-алкил, C1-C4-алкинил, арилзамещенный арил, NH2, NH-C1-C4-алкил, NH-(C1-C4-алкил)2, SO3H, SO2-алкил, SO2-алкиларил, SO2-N-(алкил)2 или SO2-N(алкил)(алкиларил); Х представляет собой O, S или NH;
R7, R8, R9 и R10 в отдельности или совместно представляют собой H, алкил, циклоалкил, арил, алкиларил, или R8 и R9 вместе являются частью 5-, 6- или 7-членного кольца,
или его фармацевтически приемлемая соль.1. Indanilidine acetylguanidine of the formula I
Figure 00000001

where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 individually or together represent H, C 1 -C 10 alkyl, halogenated having 1-6 carbon atoms, O-C 1 -C 10 - alkyl, haloalkoxy group having 1-6 carbon atoms, F, Cl, Br, I, aryl, substituted aryl, heteroaryl, OH, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O- lower alkyl substituted aryl, OC (= O) -C 1 -C 4 -alkylaryl, OC (= O) -NH-C 1 -C 4 -alkyl, OC (= O) -N- (C 1 -C 4 -alkyl ) 2 , NO 2 , CH, CF 3 , NH 2 , NH-C (= O) -C 1 -C 4 -alkyl, NH-C (= O) -NH 2 , COOH, C (= O) -OC 1 -C 4 -alkyl, C (= O) -NH 2 , C (= O) -NH-C 1 -C 4 -alkyl, C (= O) -N (C 1 -C 4 -alkyl) 2 , C 1 -C 4 -COOH, C 1 -C 4 -alkyl-C (= O) -OC 1 -C 4 -alkyl, SO 3 H, SO 2 -alkyl, SO 2 -alk ilaryl, SO 2 -N- (alkyl), SO 2 -N- (alkyl) (alkylaryl), C (= O) -R 11 , C 1 -C 10 -alkyl-C (= O) -R 11 , C 2 -C 10 -alkenyl-C (= O) -R 11 , C 2 -C 10 -alkynyl-C (= O) -R 11 , NH-C (= O) -C 1 -C 10 -alkyl-C (= O) -R 11 or OC 1 -C 11 -alkyl-C (= O) -R 11 , R 11 is C 1 -C 4 -alkyl, C 1 -C 4 -alkynyl, aryl-substituted aryl, NH 2 , NH-C 1 -C 4 -alkyl, NH- (C 1 -C 4 -alkyl) 2 , SO 3 H, SO 2 -alkyl, SO 2 -alkylaryl, SO 2 -N- (alkyl) 2 or SO 2 -N (alkyl) (alkylaryl); X represents O, S or NH;
R7, R8, R9 and R10 individually or collectively represent H, alkyl, cycloalkyl, aryl, alkylaryl, or R8 and R9 together are part of a 5-, 6- or 7-membered ring,
or a pharmaceutically acceptable salt thereof. 2. Соединение формулы I по п. 1 где R1, R2, R3, R4, R5, R6 в отдельности или совместно представляют собой H, C1-C10-алкил, галогеноалкил имеющий 1-6 атомов углерода, О-C1-C10-алкил, галогеноалкокси-группу имеющую 1-6 атомов углерода, галогены, такие как F, Cl, Br, I, арил, замещенный арил, гетероарил, замещенный гетероарил, OH, О-низший алкил, О-арил, О-низший алкиларил, О-замещенный арил, О-низший алкилзамещенный арил, O-C(=O)-C1-C4-алкиларил, O-C(= O)-NH-C1-C4-алкил, O-C(=O)-N(C1-C4-алкил)2, NO2, CN, CF3, NH2, NH-C(= O)-NH-C1-C4-алкил, NH-C(= O)-NH2, COOH, C(=O)-O-C1-C4-алкил, C(=O)-NH2, C(= O)-NH-C1-C4-алкил, C(= O)-N(C1-C4-алкил)2, C1-C4-COOH, C1-C4-алкил-C(= O)-O-C1-C4-алкил, SO3H, SO2-алкил, SO2-алкиларил, SO2-N-(алкил)2, SO2-N-(алкил)(алкиларил); C(= O)-R11, C1-C10-алкил-C(=O)-R11, C2-C10-алкенил-C(= O)-R11, C2-C10-алкинил-C(= O)-R11, NH-C(=O)-C1-C10-алкил-C(=O)-R11 или О-C1-C11-алкил-C(= O)-R11, R11 представляет собой C1-C4-алкил, C1-C4-алкинил, арилзамещенный арил, NH2, NH- C1-C4-алкил, N-(C1-C4-алкил)2, SO3H, SO2-алкил, SO2-алкиларил, SO2-N(алкил)(алкиларил), R7, R8, R9 и R10 представляют собой водород, Х представляет собой O, S или NH.2. The compound of formula I according to claim 1, wherein R1, R2, R3, R4, R5, R6 individually or together are H, C 1 -C 10 -alkyl, haloalkyl having 1-6 carbon atoms, O-C 1 - C 10 -alkyl, haloalkoxy group having 1-6 carbon atoms, halogens such as F, Cl, Br, I, aryl, substituted aryl, heteroaryl, substituted heteroaryl, OH, O-lower alkyl, O-aryl, O- lower alkylaryl, O-substituted aryl, O-lower alkyl substituted aryl, OC (= O) -C 1 -C 4 -alkylaryl, OC (= O) -NH-C 1 -C 4 -alkyl, OC (= O) - N (C 1 -C 4 -alkyl) 2 , NO 2 , CN, CF 3 , NH 2 , NH-C (= O) -NH-C 1 -C 4 -alkyl, NH-C (= O) -NH 2 , COOH, C (= O) -OC 1 -C 4 -alkyl, C (= O) -NH 2 , C (= O) -NH-C 1 -C 4 -alkyl, C (= O) -N (C 1 -C 4 -alkyl) 2 , C 1 -C 4 -COOH, C 1 -C 4 -alkyl-C (= O) -OC 1 -C 4 -alkyl, SO 3 H, SO 2 -alkyl, SO 2 -alkylaryl, SO 2- N- (alkyl) 2 , SO 2 -N- (alkyl) (alkylaryl); C (= O) -R 11 , C 1 -C 10 -alkyl-C (= O) -R 11 , C 2 -C 10 -alkenyl-C (= O) -R 11 , C 2 -C 10 -alkynyl -C (= O) -R 11 , NH-C (= O) -C 1 -C 10 -alkyl-C (= O) -R 11 or O-C 1 -C 11 -alkyl-C (= O) -R 11 , R 11 represents C 1 -C 4 alkyl, C 1 -C 4 alkynyl, aryl substituted aryl, NH 2 , NH-C 1 -C 4 alkyl, N- (C 1 -C 4 alkyl ) 2 , SO 3 H, SO 2 -alkyl, SO 2 -alkylaryl, SO 2 -N (alkyl) (alkylaryl), R7, R8, R9 and R10 are hydrogen, X is O, S or NH. 3. Соединение формулы I по пп. 1 и 2, где R1, R2, R3, R4, R5, R6 в отдельности или совместно представляют собой H, C1-C10-алкил, галогеноалкил имеющий 1-6 атомов углерода, О-C1-C10-алкил, галогеноалкокси-группу имеющую 1-6 атомов углерода, галогены, такие как F, Cl, Br, I, арил, замещенный арил, гетероарил, замещенный гетероарил, OH, О-низший алкил, О-арил, О-низший алкиларил, О-замещенный арил, О-низший алкилзамещенный арил, O-C(=O)-C1-C4-алкиларил, O-C(= O)-NH-C1-C4-алкил, O-C(= O)-N(C1-C4-алкил)2, NO2, CN, CF3, NH2, NH-C(=O)-C1-C4-алкил, NH-C(=O)-NH2, COOH, C(=O)-O-C1-C4-алкил, C(= O)-NH2, C(= O)-NH-C1-C4-алкил, C(= O)-N(C1-C4-алкил)2, C1-C4-COOH, C1-C4-алкил-C(= O)-O-C1-C4-алкил, SO3H, SO2-алкил, SO2-алкиларил, SO2-N-(алкил)2, SO2-N(алкил)(алкиларил), C(= O)-R11, C1-C10-алкил-C(= O)-R11, C2-C10-алкенил-C(= O)-R11, C2-C10-алкинил-C(=O)-R11, NH-C(=O)-C1-C10-алкил-C(= O)-R11 или О-C1-C11-алкил-C(=O)-R11, R11 представляет собой C1-C4-алкил, C1-C4-алкинил, арилзамещенный арил, NH2, NH-C1-C4-алкил, N-(-C1-C4-алкил)2, SO3H, SO2-алкил, SO2-алкиларил, SO2-N(алкил)2, SO2-N(алкил)(алкиларил), R7, R8, R9 и R10 представляют собой водород, X представляет собой О.3. The compound of formula I according to paragraphs. 1 and 2, where R1, R2, R3, R4, R5, R6 individually or collectively represent H, C 1 -C 10 -alkyl, halogenated with 1-6 carbon atoms, O-C 1 -C 10 -alkyl, haloalkoxy group having 1-6 carbon atoms, halogens such as F, Cl, Br, I, aryl, substituted aryl, heteroaryl, substituted heteroaryl, OH, O-lower alkyl, O-aryl, O-lower alkylaryl, O- substituted aryl, O-lower alkyl substituted aryl, OC (= O) -C 1 -C 4 -alkylaryl, OC (= O) -NH-C 1 -C 4 -alkyl, OC (= O) -N (C 1 - C 4 -alkyl) 2 , NO 2 , CN, CF 3 , NH 2 , NH-C (= O) -C 1 -C 4 -alkyl, NH-C (= O) -NH 2 , COOH, C (= O) -OC 1 -C 4 -alkyl, C (= O) -NH 2 , C (= O) -NH-C 1 -C 4 -alkyl, C (= O) -N (C 1 -C 4 - alkyl) 2, C 1 -C 4 -COOH, C 1 -C 4 -a keel-C (= O) -OC 1 -C 4 -alkyl, SO 3 H, SO 2 -alkyl, SO 2 -alkylaryl, SO 2 -N- (alkyl) 2, SO 2 -N (alkyl) (alkylaryl) , C (= O) -R 11 , C 1 -C 10 -alkyl-C (= O) -R 11 , C 2 -C 10 -alkenyl-C (= O) -R 11 , C 2 -C 10 - alkynyl-C (= O) -R 11 , NH-C (= O) -C 1 -C 10 -alkyl-C (= O) -R 11 or O-C 1 -C 11 -alkyl-C (= O ) -R 11 , R 11 represents C 1 -C 4 -alkyl, C 1 -C 4 -alkynyl, aryl-substituted aryl, NH 2 , NH-C 1 -C 4 -alkyl, N - (- C 1 -C 4 -alkyl) 2 , SO 3 H, SO 2 -alkyl, SO 2 -alkylaryl, SO 2 -N (alkyl) 2 , SO 2 -N (alkyl) (alkylaryl), R7, R8, R9 and R10 are hydrogen, X represents O. 4. Способ получения соединения формулы I по п. 1, включающий взаимодействие соединения формулы V
Figure 00000002

где R1, R2, R3, R4, R5 и R6 определены в п. 1;
Y является уходящей группой, выбираемой из -O-(С1-С4)-алкила, галогена или имидазолила,
с гуанидином формулы VI
Figure 00000003

где R7, R8, R9 и R10 определены в п. 1,
и при желании превращение продукта реакции в фармацевтически переносимые соли.4. A method of obtaining a compound of formula I according to claim 1, comprising reacting a compound of formula V
Figure 00000002

where R1, R2, R3, R4, R5 and R6 are as defined in claim 1;
Y is a leaving group selected from —O- (C 1 -C 4 ) -alkyl, halogen or imidazolyl,
with guanidine of formula VI
Figure 00000003

where R7, R8, R9 and R10 are defined in paragraph 1,
and if desired, converting the reaction product into pharmaceutically acceptable salts. 5. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения аритмии сердца. 5. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment of cardiac arrhythmias. 6. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения или профилактики инфаркта миокарда. 6. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment or prevention of myocardial infarction. 7. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения или профилактики грудной жабы. 7. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment or prevention of angina pectoris. 8. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения или профилактики ишемических состояний сердца. 8. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment or prevention of ischemic conditions of the heart. 9. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения или профилактики ишемических состояний периферической и центральной нервной системы и апоплексии. 9. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment or prevention of ischemic conditions of the peripheral and central nervous system and apoplexy. 10. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения или профилактики ишемических состояний периферийных органов и конечностей. 10. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment or prevention of ischemic conditions of peripheral organs and limbs. 11. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения шоковых состояний. 11. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment of shock conditions. 12. Применение соединения формулы I по п. 1 для изготовления медикамента для использования в хирургических операциях и трансплантациях органов. 12. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for use in surgical operations and organ transplants. 13. Применение соединения формулы I по п. 1 для изготовления медикамента для консервирования и хранения трансплантатов для хирургических операций. 13. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the preservation and storage of transplants for surgical operations. 14. Применение соединения формулы I по п. 1 для изготовления лекарственного средства для лечения заболеваний, первичной или вторичной причиной которых является разрастание клеток, и, таким образом, его применение в качестве антиатеросклеротического средства или агента против поздних осложнений после диабета, раковых заболеваний, фиброзных заболеваний, таких как фиброз легких, фиброз печени или фиброз почек, и гиперплазии простаты. 14. The use of the compounds of formula I according to claim 1 for the manufacture of a medicament for the treatment of diseases whose primary or secondary cause is cell proliferation, and thus its use as an anti-atherosclerotic agent or agent against late complications after diabetes, cancer, fibrotic diseases diseases such as pulmonary fibrosis, liver fibrosis or kidney fibrosis, and prostatic hyperplasia. 15. Применение соединения формулы I по п. 1 для изготовления научного средства для ингибирования Na+/Н+-антипорта и диагностики гипертонии и пролиферативных заболеваний.15. The use of the compounds of formula I according to claim 1 for the manufacture of a scientific agent for the inhibition of Na + / H + antiport and the diagnosis of hypertension and proliferative diseases. 16. Применение соединения формулы I по п. 1 для изготовления лекарственного препарата для лечения или профилактики нарушений липидного метаболизма. 16. The use of the compounds of formula I according to claim 1 for the manufacture of a medicinal product for the treatment or prevention of disorders of lipid metabolism. 17. Лекарственное средство, включающее эффективное количество формулы I по п. 1. 17. A medicament comprising an effective amount of formula I according to claim 1.
RU97113146/04A 1996-07-30 1997-07-29 Substituted indanylidine acetyl guanidines, method of preparing thereof, use of medicinal or diagnostic agents and medical agents comprising said compounds RU2176638C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96112275A EP0837055A1 (en) 1996-07-30 1996-07-30 Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
EP96112275.1 1996-07-30

Publications (2)

Publication Number Publication Date
RU97113146A true RU97113146A (en) 1999-05-27
RU2176638C2 RU2176638C2 (en) 2001-12-10

Family

ID=8223055

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97113146/04A RU2176638C2 (en) 1996-07-30 1997-07-29 Substituted indanylidine acetyl guanidines, method of preparing thereof, use of medicinal or diagnostic agents and medical agents comprising said compounds

Country Status (29)

Country Link
US (1) US5900436A (en)
EP (2) EP0837055A1 (en)
JP (1) JP4039589B2 (en)
KR (1) KR980009236A (en)
CN (1) CN1064351C (en)
AR (1) AR008095A1 (en)
AT (1) ATE207888T1 (en)
AU (1) AU715187B2 (en)
BR (1) BR9704131A (en)
CA (1) CA2211982C (en)
CZ (1) CZ241197A3 (en)
DE (1) DE69707777T2 (en)
DK (1) DK0822182T3 (en)
ES (1) ES2164283T3 (en)
HR (1) HRP970424B1 (en)
HU (1) HUP9701316A3 (en)
ID (1) ID17565A (en)
IL (1) IL121407A0 (en)
MX (1) MX9705737A (en)
NO (1) NO308213B1 (en)
NZ (1) NZ328440A (en)
PL (1) PL321392A1 (en)
PT (1) PT822182E (en)
RU (1) RU2176638C2 (en)
SI (1) SI0822182T1 (en)
SK (1) SK282128B6 (en)
TR (1) TR199700704A2 (en)
TW (1) TW445251B (en)
ZA (1) ZA976735B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345283B (en) 2008-12-31 2017-01-24 Ardelyx Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
JP6377132B2 (en) 2013-04-12 2018-08-22 アーデリクス，インコーポレーテッド NHE3-binding compounds and methods of inhibiting phosphate transport
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EA201991676A1 (en) 2017-01-09 2020-01-30 Арделикс, Инк. NHE-MEDIATED ANTI-PORT INHIBITORS
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (en) * 1989-09-06 1991-03-07 Hoechst Ag BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINE AND THE MEDICINE CONTAINING IT
DE4421536A1 (en) * 1994-06-20 1995-12-21 Hoechst Ag Phenyl-substituted alkenylcarboxylic acid guanidines bearing perfluoroalkyl groups, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them

Similar Documents

Publication Publication Date Title
US5698738A (en) N-nitroso-N-substituted hydroxylamines as nitric oxide donors
JPH069545A (en) O-substituted benzoylguanidine, its production, its use as medicine or diagnostic agent, and medicine containing it
JPS60252461A (en) (s)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide, manufacture and pharmaceutical composition
KR960041152A (en) Fluorophenyl-substituted alkenylcarboxylic acid guanidides, their preparation, their use as medicaments or diagnostic agents and medicaments containing them
RU97113146A (en) SUBSTITUTED INDANYLIDINACETHYLGUANIDINES, METHOD FOR PRODUCING THEM, USE AS MEDICINES OR DIAGNOSTIC MEDICINES AND MEDICINES CONTAINING THESE COMPOUNDS
KR20000070233A (en) Bis-Sulfonamides Hydroxamic Acids as MMP Inhibitors
RU94037235A (en) Inhibitor of uterus fibrosis
JP3875731B2 (en) 3,5-substituted aminobenzoylguanidines, their preparation, their use as medicaments or diagnostics and medicaments containing them
RU97109003A (en) SUBSTITUTED 2-NAPTOYLGUANIDINES, METHOD FOR PRODUCING THEM AND MEDICINE ON THEIR BASIS
SK62996A3 (en) Substituted benzyloxycarbonyl guanidines, method of their producing, their use and drugs containing them
US4150146A (en) Process for the preparation of unsymmetrically 1,3-disubstituted nitroso ureas
KR970015568A (en) Substituted Benzoylguanidine, Method of Making the Same, Use thereof as a medicament or a diagnostic agent, and a pharmaceutical comprising the same
CA2486872A1 (en) Nf-kb inhibitors and uses thereof
EP0007184B1 (en) Urea derivatives, processes for preparing them and compositions containing them
RU98101090A (en) MONO- AND DISULPHOSE SUBSTITUTED ANTHRAKHINONES AND THEIR APPLICATION FOR TREATMENT OF BONE MATRIX DISORDERS
RU96107258A (en) ANTIOARRHYTHMIC AND CARDIOPROTECTIVE SUBSTITUTED INDENOYILGUANIDINES
KR970006282A (en) 4-Fluoroalkyl-substituted benzoylguanidines, their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
RU95115408A (en) SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING THERE, CONTAINING THEIR MEDICINAL PRODUCT, METHOD OR MEANS FOR ITS PRODUCTION, METHOD OF TREATMENT
US4224242A (en) N-[3-(lower)alkylaminopropyl]-N'-(disubstituted)phenylureas
RU2218329C2 (en) Ortho-substituted benzoylguanidines, method for preparing, using as medicinal or diagnostic agents and medicinal preparation based on thereof also
RU97109528A (en) ORTO-SUBSTITUTED BENZOILGUANIDINES, THE WAY OF THEIR RECEPTION, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE
RU2227796C2 (en) Ortho-substituted benzoylguanidines, method for their preparing and medicinal agent based on thereof
KR970026597A (en) Sulfonylamino-substituted benzoylguanidines, methods for their preparation, their use as medicaments or diagnostic auxiliaries and medicaments containing same
RU97102136A (en) SUBSTITUTED GUANIDIDES OF THIOPHENYLALKENYL CARBONIC ACID, METHOD OF THEIR RECEIVING THEM, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE
RU97102581A (en) ORTHO-SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING, USE AS MEDICINES OR DIAGNOSTIC MEDICINES, AND ALSO THE DRUG ON THEIR BASIS